Mereo BioPharma Group PLC (MREO)
| Market Cap | 335.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -224.15M |
| Shares Out | 108.25M |
| EPS (ttm) | -3.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $3.10 |
| Previous Close | $2.98 |
| Change ($) | 0.12 |
| Change (%) | 4.03% |
| Day's Open | 3.08 |
| Day's Range | 2.94 - 3.14 |
| Day's Volume | 1,214,485 |
| 52-Week Range | 1.19 - 4.71 |
Cancer Focus Fund LP, established in collaboration with The University of Texas MD Anderson Cancer Center and Mereo BioPharma Group plc (NASDAQ: MREO), has entered into a funding agreement. The partners...
LONDON and REDWOOD City, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology an...
-- Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta ---- Further Strengthened Management Team ---- OncXerna Global Licensing Agreement for Navicixizumab ---- Stre...
LONDON and REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...
LONDON and REDWOOD CITY, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...
LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...
LONDON and REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and...
Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx's existing bone franchise
LONDON and REDWOOD CITY, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...
LONDON and REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...
LONDON and REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...
LONDON and REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...
LONDON and REDWOOD CITY, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on on...
On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020
Mereo BioPharma's (MREO) CEO Denise Scots-Knight on 2020 Interim Financial Results Conference Call Transcript
On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020
LONDON and REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on ...
LONDON and REDWOOD CITY, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on ...
LONDON and REDWOOD CITY, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on o...
LONDON and REDWOOD CITY, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on o...
Operational progress, positioned for clinical milestones in oncology and rare diseases Operational progress, positioned for clinical milestones in oncology and rare diseases
Plans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease Product Portfolio Plans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease Product Portfolio
LONDON and REDWOOD CITY, Calif., March 27, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on r...
LONDON and REDWOOD CITY, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced that it has entered into a Securities P...
Additional Data Demonstrate Dose-Dependent Increase in Bone Strength Stiffness and Failure Load at the Radius as Measured by Finite Element Analysis, a Second Prespecified Primary Endpoint, Reaching Sta...
Oncologie receives exclusive global license to develop and commercialize navicixizumab
Liver Therapy Forum weekly digest provides an overview of what's happening in therapeutics for endocrine disorders in 2019. The focus this week is Mereo BioPharma.
Mereo BioPharma has been struggling lately, but the selling pressure may be coming to an end soon.
In 2019, the American Cancer Society estimates that about 22,530 women will receive a new diagnosis of ovarian cancer and that about 13,980 women will die from this disease in the United States alone.
About MREO
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197... [Read more...]
| Industry Biotechnology | Founded 2015 |
| CEO Denise Scots-Knight | Employees 38 |
| Stock Exchange NASDAQ | Ticker Symbol MREO |
Analyst Forecasts
According to one analyst, the rating for MREO stock is "Strong Buy" and the 12-month stock price forecast is 664.20.